CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, today announced its participation in four upcoming conferences.
- 12th Annual Structure-Based Drug Design Conference at the Royal Sonesta Hotel in Cambridge, MA, on Friday, June 8th, at 8:40 AM
- 2012 CEO Biotech Conference at the Mandarin Oriental Boston Hotel in Boston, MA, on Tuesday, June 12th, at 1:00 PM
- Summer Symposium 2012: Epigenetics, Plasticity, and Cancer at The David H. Koch Institute for Integrative Cancer Research on Thursday, June 14th, from 8:30 AM to 4:30 PM
- 2012 BIO International Convention at the Boston Convention & Exhibition Center on Tuesday, June 19th, at 2:00 PM, in a panel titled, “The ‘32 Flavors’ of Research Deal Structures: Looking Beyond Vanilla Term Sheets”
About Epizyme
Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a family of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.
Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). www.epizyme.com